Stocks of Takeda Pharmaceutical Co ADR (NYSE:TAK) traded higher last session on Wall Street, up 0.30% to $13.33.
TAK stock price is now -5.67% away from the 50-day moving average and -4.06% away from the 200-day moving average. The market capitalization of the company currently stands at $42.26B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $20, BofA Securities recently Upgraded its rating from Neutral to Buy for Takeda Pharmaceutical Co ADR (NYSE: TAK). On July 19, 2022, Cowen Upgraded its previous ‘Market Perform’ rating to ‘Outperform’ on the stock increasing its target price from $21 to quote $24, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, Giles Richard Platford, President, Plasma-Derived Ther bought 19,073 shares of the company’s stock on Aug 23 ’24. The stock was bought for $284,951 at an average price of $14.94. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 24 ’24, 10% Owner TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares of the business’s stock. A total of $29,999,994 was realized by selling the stock at an average price of $8.10. This leaves the insider owning 3,755,583 shares of the company worth $50.06 million. A total of 0.02% of the company’s stock is owned by insiders.
During the past 12 months, Takeda Pharmaceutical Co ADR has had a low of $12.57 and a high of $15.08. As of last week, the company has a debt-to-equity ratio of 0.73, a current ratio of 1.28, and a quick ratio of 0.77. According to the stock market information, the enterprise value for the company is $4772289052672, which is based on a 22.11 price-to-earnings ratio, a 0.66 price-to-earnings-growth ratio, and a beta of 0.55. The fifty day moving average price for TAK is $14.1616 and a two-hundred day moving average price translates $13.89845 for the stock.
The latest earnings results from Takeda Pharmaceutical Co ADR (NYSE: TAK) was released for 2024-09-30. The net profit margin was 6.36% and return on equity was 4.02% for TAK.
